Optimizing adipose-derived stem cell therapy for diabetic foot ulcers

Figure 7 Fate of adipose-derived mesenchymal stem cells after transplantation in diabetic foot ulcer models. Adipose-derived mesenchymal stem cells (ADSCs) were labeled with 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindodicarbocyanine perchlorate (DiD) and detected by an in vivo imaging system. A and B: Images of DiD-labeled ADSCs after subcutaneous or intramuscular injection on the dorsal side of the hindleg in diabetic foot ulcer model mice; C: The fluorescence intensity of DiD in DiD-labeled ADSCs gradually decreased during the four weeks after transplantation, n = 3; D: Fluorescence intensity of DiD in DiD-labeled ADSCs at various time points, n = 3; E: Images of DiD-labeled ADSCs after subcutaneous injection on the right hindfoot in the diabetic foot ulcers model rats at different time points. The data are presented as mean ± SD. ^aP < 0.05 vs intramuscular injection.